Jaka jest cena za ReShape Lifesciences Inc. (RSLS)

Cena za ReShape Lifesciences Inc. (RSLS) wynosi $3.92

Jaka jest kapitalizacja rynkowa dla ReShape Lifesciences Inc. (RSLS)

Kapitalizacja rynkowa dla ReShape Lifesciences Inc. (RSLS) wynosi $2.34M

ReShape Lifesciences Inc. (RSLS) Marża Operacyjna

Founded in 2002 and based in San Clemente, California, ReShape Lifesciences Inc. operates as a medical device company dedicated to addressing obesity and metabolic diseases. The company's market extends throughout the United States, Australia, Europe, and globally. Its diverse product lineup features the Lap-Band System, a minimally invasive, long-term solution for severe obesity that offers an alternative to more extensive surgical interventions like gastric bypass or sleeve gastrectomy. Under development is the ReShape Vest system, an investigational, minimally invasive device that is laparoscopically implanted around the stomach to assist obese and morbidly obese patients in losing weight, without cutting or permanently removing parts of the stomach or bypassing any section of the gastrointestinal tract. ReShape also supports patients through the ReShapeCare virtual health coaching program, a telehealth service aimed at promoting healthy lifestyle adjustments for individuals undergoing medically supervised weight management. Additionally, the company is conducting preclinical development for ReShape Diabetes Bloc-Stim Neuromodulation, a technology intended for the treatment of type 2 diabetes mellitus. Among its offerings is the Obalon Balloon System, a swallowable capsule used to monitor and display the balloon's exact position during its placement. The company, initially incorporated as EnteroMedics Inc., changed its name to ReShape Lifesciences Inc. in 2017.

Rok	Marża operacyjna	Zmień
Za mało danych dla podanych dat.

Rok

Marża operacyjna

Zmień

Za mało danych dla podanych dat.

Firma	Marża operacyjna	Różnica w marży operacyjnej	Kraj
Abbott Laboratories ABT.US	17.03%	-	US
Stryker Corporation SYK.US	22.03%	-	US
Medtronic plc MDT.US	17.86%	-	IE
Boston Scientific Corporation BSX.US	21.46%	-	US
Edwards Lifesciences Corporation EW.US	28.09%	-	US

Firma

Marża operacyjna

Różnica w marży operacyjnej

Kraj